Agenda

(members only)

(members only)

(by invitation only)

(board members and invited guests only)

John Murphy III
President and CEO, AAM

2025 Champions of Access Award 

Join Dr. Jacqueline Corrigan-Curay for an insightful keynote address that explores the current priorities and future directions of the FDA’s Center for Drug Evaluation and Research (CDER).  Dr. Corrigan-Curay will share her perspective on CDER’s pivotal role in advancing generics and biosimilars, addressing challenges in regulatory science, and fostering innovation in drug development.

Jacqueline Corrigan-Curay, JD, M.D.
Principal Deputy Center Director, Center for Drug Evaluation and Research (CDER), FDA

2024 ushered in dramatic changes in the biosimilars market. The adalimumab biosimilars market revealed new strategies for adoption, all while price deflation challenges facing infused biosimilars intensified. The Food and Drug Administration took important steps to help streamline biosimilar development even as biosimilar pipelines continued to exclude scores of high spend brand biologics. As the use of biologic medicines grow, join us for a timely discussion on the long-term sustainability of biosimilar competition.

Murray Aitken
Executive Director, IQVIA Institute for Human Data Science

Moderator: Craig Burton
Executive Director, Biosimilars Council
Senior Vice President, Policy and Strategic Alliances, AAM

President Trump’s second term is already drawing headlines. President Trump has leaned into his populist agenda through the selection of his nominees and the creation of the Department of Government Efficiency (DOGE). Tariffs, tax cuts and more are on the agenda—and DC is braced for changes to key healthcare agencies. This panel of Washington insiders will discuss the issues and the leaders they’re following to navigate the next four years.

Alex Brill
Senior Fellow, American Enterprise Institute

Paul Heldman
Research Analyst, Health Policy, Nephron Research LLC

Dean Rosen
Partner, Mehlman Consulting

Moderator: Katherine Raab
Vice President, Federal Government Affairs, AAM

Doug Long
Vice President, Industry Relations, IQVIA

As the healthcare landscape evolves, commercial, employer and government payers, pharmacy benefit managers and pharmacies must seek new ways to offer and contract for networks and services that meet patient needs and lower costs. To effectively compete in this environment, retail, specialty and mail service pharmacies must account for a demand in convenience and changing patient and payer preferences while responding to industry headwinds— including workforce challenges and declining reimbursement. There is no one-size-fits-all approach. This fireside conversation will explore these and other topics critical to understanding the pharmacy of the future.

John Lavin
Chief Revenue Officer, Stellus Rx

Moderator: Michael Sargent
Senior Director, Policy, AAM

(members only)

John Murphy III
President and CEO, AAM

The launch and evolution of the adalimumab biosimilars market exposed varying strategies to biosimilar adoption by manufacturers, PBMs and healthcare plans. As new biosimilars come to market, what lessons can be found in the adalimumab market? What new challenges or opportunities may result from evolving provider acceptance as well as implementation of IRA price controls? This fireside conversation will explore these and other topics critical to driving biosimilar uptake.

Joshua Fredell, PharmD
Vice President, PBM & Specialty Product Development, CVS Health

Moderator: Craig Burton
Executive Director, Biosimilars Council
Senior Vice President, Policy and Strategic Alliances, AAM

Alex Azar
Former Secretary, U.S. Department of Health and Human Services

Moderator: John Murphy III
President and CEO, AAM

Join Dr. Scott Gottlieb as he provides an in-depth look at challenges and opportunities facing the healthcare industry and regulatory agencies. Drawing from his extensive experience at the helm of the FDA, Dr. Gottlieb will offer a unique perspective on the intersection of industry goals and regulatory mandates—and highlight strategies for collaboration and progress. Don’t miss this opportunity to gain expert insights into the evolving landscape of healthcare regulation and its implications for the future.

Scott Gottlieb, M.D.
Former Commissioner, FDA
Former Senior Advisor, CMS

Moderator: John Murphy III
President and CEO, AAM

Join us for an engaging session where global industry leaders take the stage to discuss the future of generics and biosimilars. This dynamic conversation will delve into pressing challenges, emerging opportunities, and innovative strategies shaping the healthcare landscape.  In this exclusive forum, CEOs will share insights on leadership, navigating market disruptions, and driving progress—while also fielding candid questions.

Moderator:  Scott Gottlieb, M.D. 
Former Commissioner, FDA
Former Senior Advisor, CMS

Vinita Gupta
Chief Executive Officer, Lupin

Chirag Patel
President and Co-Chief Executive Officer, Amneal Pharmaceuticals

John Murphy III
President and CEO, AAM